Very interesting. Thanks for sharing. I am still not sold on the whole artificial pancreas thing - I think it offers some promise for improved treatment definitely, but I don't think it's going to be the "cure" so many people hope for.
My biggest concern about this study is that the range of what was considered a "normal" BG was 70-180 mg/dL. If you stay in the 170s for several hours, that's not good. I also have concerns about the accuracy of the CGMs. They are still not terribly accurate and I would be worried that my CGM would signal that I'm low and shut off my pump when I'm really in range, and then I'd end up really high (if not in DKA).
I guess I question some of these efforts when there are still so many other issues, like inaccurate home meters and T1s who aren't able to afford the current standard of care (pumps, for example). Are we just creating another mode of treatment that will be out of reach for even more people?
I'm a bit leary of the CGM myself at this point, though I haven't even started pumping yet. You make an excellent point about access and affordability that I hadn't considered.
My concerns also. Afraid I don't have faith or trust in the AP. I've also thought of the increasing gap of what's affordable for most people & what the expense will be regarding insurance rates.
It is progress, but even when this technology becomes available in America (and it already is in use in Europe) it is but one step on a long road.
While it introduces an element of safety for CGM+pump users, it will not see it's full potential until even quicker acting insulins are in use. They are also in development. Also being tested are better CGM sensors based on the Minimed sensor also approved in Europe. It is smaller, more comfortable and around 10-15% more accurate. I think the utility of the suspend feature coupled with the new sensor will enhance safety, patient satisfaction and compliance once they are approved by the FDA. With luck I hope we can start using them sooner rather than later. Thankfully their widespread use in Europe should help get them to market faster rather than if they were starting from scratch here.
I also don't know if the 19% reduction in time spent below the low glucose threshold in patients using the MiniMed Paradigm System is a big enough improvement for me. I guess its better than nothing but as its been said this is a first step.